These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 33586516)

  • 1. Inflammatory Mechanisms in Parkinson's Disease: From Pathogenesis to Targeted Therapies.
    Lee SYH; Yates NJ; Tye SJ
    Neuroscientist; 2022 Oct; 28(5):485-506. PubMed ID: 33586516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies.
    Rocha NP; de Miranda AS; Teixeira AL
    Biomed Res Int; 2015; 2015():628192. PubMed ID: 26295044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
    Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
    J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy.
    Qian L; Flood PM; Hong JS
    J Neural Transm (Vienna); 2010 Aug; 117(8):971-9. PubMed ID: 20571837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
    J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic Regulation of Neuroinflammation in Parkinson's Disease.
    Rasheed M; Liang J; Wang C; Deng Y; Chen Z
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Involvement of Neuroinflammation in the Onset and Progression of Parkinson's Disease.
    Jurcau A; Andronie-Cioara FL; Nistor-Cseppento DC; Pascalau N; Rus M; Vasca E; Jurcau MC
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of Toll-like receptors and neuroinflammation in Parkinson's disease.
    Heidari A; Yazdanpanah N; Rezaei N
    J Neuroinflammation; 2022 Jun; 19(1):135. PubMed ID: 35668422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation in Parkinson's Disease: Mechanisms and Therapeutic Implications.
    Pajares M; I Rojo A; Manda G; Boscá L; Cuadrado A
    Cells; 2020 Jul; 9(7):. PubMed ID: 32674367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related biomarkers for Parkinson's disease.
    Abdi IY; Ghanem SS; El-Agnaf OM
    Neurobiol Dis; 2022 Aug; 170():105771. PubMed ID: 35598675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease.
    Marogianni C; Sokratous M; Dardiotis E; Hadjigeorgiou GM; Bogdanos D; Xiromerisiou G
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanisms of white matter injury and immune system crosstalk in promoting the progression of Parkinson's disease: a narrative review.
    Ma W; Geng Y; Liu Y; Pan H; Wang Q; Zhang Y; Wang L
    Front Aging Neurosci; 2024; 16():1345918. PubMed ID: 38863783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
    Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
    Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.
    Tansey MG; Goldberg MS
    Neurobiol Dis; 2010 Mar; 37(3):510-8. PubMed ID: 19913097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microglia in Parkinson's Disease.
    Ho MS
    Adv Exp Med Biol; 2019; 1175():335-353. PubMed ID: 31583594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair.
    Vivekanantham S; Shah S; Dewji R; Dewji A; Khatri C; Ologunde R
    Int J Neurosci; 2015; 125(10):717-25. PubMed ID: 25364880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson's disease.
    Kip E; Parr-Brownlie LC
    Ageing Res Rev; 2022 Jun; 78():101618. PubMed ID: 35395416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson's disease.
    Panaro MA; Cianciulli A
    Curr Pharm Des; 2012; 18(2):200-8. PubMed ID: 22229581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease.
    Panicker N; Saminathan H; Jin H; Neal M; Harischandra DS; Gordon R; Kanthasamy K; Lawana V; Sarkar S; Luo J; Anantharam V; Kanthasamy AG; Kanthasamy A
    J Neurosci; 2015 Jul; 35(27):10058-77. PubMed ID: 26157004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease.
    Gorelenkova Miller O; Behring JB; Siedlak SL; Jiang S; Matsui R; Bachschmid MM; Zhu X; Mieyal JJ
    Antioxid Redox Signal; 2016 Dec; 25(18):967-982. PubMed ID: 27224303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.